Covid treatment: Govt removes export ban on hydroxychloroquine

News

Covid treatment: Govt removes export ban on hydroxychloroquine

Our Burea New Delhi | Updated on June 18, 2020 Published on June 18, 2020

The drug hydroxychloroquine   -  REUTERS

Exports can now be made freely to all countries

The Centre has removed the ban on export of hydroxychloroquine (HCQ) — the anti-malaria drug being used as a possible cure for Covid-19 in many countries — and has made it freely exportable.

The earlier notification prohibiting exports has been amended to change the export policy of HCQ Active Pharmaceutical Ingredients (API) and its formulations from ‘prohibited’ to ‘free’ with immediate effect, according to the latest notification issued by the Directorate General of Foreign Trade on Thursday.

This means that HCQ can now be exported without special nod from the government on a purely commercial basis based on demand.

The government had banned export of the medicine on March 25 as it had feared a shortfall in supplies with the rapid spread of the Covid-19 across the country.

However, following a request for HCQ supplies made by the US and some other countries, India decided the following month to export the drug on a case-to-case basis.

On April 30, the MEA said that as there was adequate supply of HCQ in the country, India was exporting it to 87 countries to help them meet their Covid-19 related health needs.

Published on June 18, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
Border trouble: Ahead of all-party meet, Congress questions PM